Consensus Document on the Overlap Phenotype COPD–Asthma in COPD

Soler-Cataluña, Juan José; Cosío, Borja G.; Izquierdo, José Luis; Lόpez-Campos, José Luís; Marín, J.; Agüero, Ramón; Baloira, Adolfo; Carrizo, Santiago; Esteban, Cristóbal; Gáldiz, Juan B.; González, Miguel; Miravitlles, Marc; Monsó, Eduard; Montemayor, Teodoro; Morera, Josep; Ortega, Francisco; Peces-Barba, Germán; Puente, Luis; Rodríguez, José Miguel; Sala, Ernest; Sauleda, Jaume; Soriano, Joan B.; Viejo, José Luís

doi:10.1016/j.arbr.2012.06.017

Cited by 213 publications

(143 citation statements)

References 27 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…A small pro- 17,41,48 . An important phenotype is COPD overlapping bronchial asthma that is characterised by the presence of either 2 major criteria, or 1 major and at least 2 minor criteria showing a persistent combination of clinical presentation that is typical for both conditions 3,8,42,[49][50][51] . Table 1 gives an overview of those 6 basic COPD phenotypes, which occasionally might occur simultaneously in clinical practice (e.g.…”

Section: Clinical Disease Course and Phenotypesmentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care

Koblížek

Chlumský²,

Zindr³

et al. 2013

BIOMED PAP

125

116

View full text Add to dashboard Cite

Section: Clinical Disease Course and Phenotypesmentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care

Koblížek

Chlumský²,

Zindr³

et al. 2013

BIOMED PAP

125

116

View full text Add to dashboard Cite

“…Доказательная база тиотропия. Тиотропий обладает большой доказательной базой в отношении эффек тивности и безопасности терапии ХОБЛ, поэтому может быть препаратом выбора в качестве дополне ния к иГКС или иГКС / ДДБА у пациентов с сочета нием БА и ХОБЛ [18]. В международном многоцент ровом плацебо контролируемом РКИ (n = 472) оценивались эффективность и безопасность добав ления тиотропия (порошковый ингалятор, 18 мкг в сутки) к исходной терапии у больных с сочетанием БА и ХОБЛ [19].…”

Section: сочетание ба и хоблunclassified

Consensus report: indications for use of long-acting antimuscarinic tiotropium in the treatment of bronchial asthma

Chuchalin¹,

Авдеев²,

Айсанов³

et al. 2015

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

“…These major and minor criteria differ slightly from the ones proposed by Sin et al 166 Both of those reports differ from the approach recommended in the 2015 Global Initiative for Asthma (GINA) and GOLD recommendations. Several other articles have been written on diagnostic criteria, [165][166][167] all with differing opinions. This lack of consensus affects our understanding of the impact, management and outcomes of ACO.…”

Section: Box 2 Preventing Acute Exacerbation In Stable Copdmentioning

confidence: 99%

“…First, there is no universally accepted definition or diagnostic criteria for ACO. The Spanish consensus paper 165 agreed upon a combination of six major and minor criteria, which included both clinical and physiologic components. These major and minor criteria differ slightly from the ones proposed by Sin et al 166 Both of those reports differ from the approach recommended in the 2015 Global Initiative for Asthma (GINA) and GOLD recommendations.…”

Section: Box 2 Preventing Acute Exacerbation In Stable Copdmentioning

confidence: 99%

CTS position statement: Pharmacotherapy in patients with COPD—An update

Bourbeau

Bhutani

Hernández

et al. 2017

Canadian Journal of Respiratory, Critical Care, and Sleep Medic

View full text Add to dashboard Cite

RATIONALE: Since the last published Canadian Thoracic Society (CTS) COPD guideline in 2007 and the 2008 update -highlights for primary care, many new clinical trials have challenged COPD treatment practices. The current Canadian position statement provides the reader with an update on pharmacotherapy of patients with COPD as reviewed by the CTS. OBJECTIVES: The objectives of this position statement are: 1) to summarize the literature on topics relevant to the pharmacological therapy of patients with stable COPD; and 2) to provide clinical guidance with evidence-based recommendations and expert-informed key messages for the pharmacological therapy for patients with stable COPD. METHODS: The authors systematically reviewed the relevant literature focusing on randomized controlled trials and when available, systematic reviews of randomized controlled trials. The proposed key messages, based on scientific evidence and expert-informed opinion, were agreed upon by a majority consensus. MAIN RESULTS: There is typically a significant delay in seeking medical care by patients with dyspnea, often waiting until symptoms affect the performance of activities of daily living. The diagnosis of COPD requires spirometry to confirm the presence of airflow obstruction in any patient presenting with symptoms and/or risk factors of COPD. An effective management plan for individuals with COPD should include: smoking cessation, vaccination and education. A number of non-pharmacological treatments are available for COPD patients with symptoms to improve outcomes such as self-management with coaching from a health care professional; pulmonary rehabilitation; supplemental oxygen in selected patients; and surgery.Current pharmacotherapy for COPD has been shown to alleviate symptoms and prevent exacerbations and related complications such as hospital admissions. In symptomatic patients with stable COPD not having or having infrequent exacerbation, treatment should be started with inhaled LAMA or LABA monotherapy, and if experiencing persistent or increased dyspnea, exercise intolerance, and/or reduced health status despite use of monotherapy, patients should be considered for treatment "step up" with an inhaled LAMA plus LABA dual therapy. In this situation, the use of a single inhaler would be preferred to simplify the treatment regimen and minimize the cost. In patients with stable COPD experiencing exacerbations despite the use of LAMA or LABA monotherapy, treatment "step up" with inhaled LAMA plus LABA dual therapy should be considered unless a patient has concomitant asthma (Asthma/COPD overlap (ACO)). There has been recent interest in using biomarkers to identify patients who are more likely to respond to ICS. Most of the studies have demonstrated that high blood eosinophils could be valuable to predict an increase response in terms of reduction of exacerbation rate when treated with combination ICS/LABA; there is still uncertainty about the exact cut-off level of blood eosinophils having potential therapeutic value. If a pa...

show abstract

Consensus Document on the Overlap Phenotype COPD–Asthma in COPD

Cited by 213 publications

References 27 publications

Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care

Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care

Consensus report: indications for use of long-acting antimuscarinic tiotropium in the treatment of bronchial asthma

CTS position statement: Pharmacotherapy in patients with COPD—An update

Contact Info

Product

Resources

About